Esperion Therapeutics (ESPR) Cash from Investing Activities Growth (5y) (2017 - 2024)
Esperion Therapeutics (ESPR) Cash from Investing Activities Growth (5y) (2017 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Esperion Therapeutics | 799.30 Mn | 643.14 Mn | 45.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 49.94% |
| Jun 30, 2024 | -14.90% |
| Mar 31, 2024 | -14.89% |
| Jun 30, 2023 | -11.13% |
| Mar 31, 2023 | -3.76% |
| Dec 31, 2022 | -17.54% |
| Sep 30, 2022 | 17.70% |
| Jun 30, 2022 | -28.68% |
| Mar 31, 2022 | -25.55% |
| Dec 31, 2021 | -53.47% |
| Dec 31, 2020 | -34.32% |
| Sep 30, 2020 | 15.58% |
| Jun 30, 2020 | 15.69% |
| Mar 31, 2020 | 19.75% |
| Dec 31, 2019 | 40.63% |
| Sep 30, 2019 | -54.38% |
| Jun 30, 2019 | 138.39% |
| Mar 31, 2019 | 108.74% |
| Dec 31, 2018 | 47.74% |
| Sep 30, 2018 | 37.92% |